DNA (deoxyribonucleic acid) is a complex molecule that contains an unique genetic code (or called "bases") giving biological instructions to build and maintain the whole human body. The order, or sequence, of these "bases" determines what biological instructions are contained in a strand of DNA, known as a gene. Genes only make up about 1 percent of the DNA sequence of the human genome, commonly referred to as the Exome. The human genome is made of 3 billion base pairs in total. Any change or alteration in the gene is known as a mutation Example: Alteration in the EGFR gene is known as EGFR mutation.
Cancer is a genetic disease and there are more than 100 types named after the organs or tissues that it affects. Genomics provides genetic insights to tailor treatments that prevent the misery of misdiagnosis, needless hospital visits and ineffective chemotherapy thereby enabling an increase in survival rates. Three decades ago, the 5-year survival rate for all cancers combined was 50%. In the last decade, the 5-year relative survival rates for the five most common cancers were: breast, 90%; prostate, 100%; lung, 16%; colorectal, 67%; and bladder, 81%. Kyvor is dedicated to bring hope and life to patients with the promise that the end of cancer begins here…
Kyvor is a genome intelligence startup providing physicians with an actionable report of tailored theranostic solutions unique to each person's cancer aiming to reduce the exorbitant cancer mortality rate. Kyvor offers whole exome assay to analyze the patient tumor’s genetic make- up and match with relevant and latest therapies, that are likely to be more effective and cause fewer side effects. Kyvor envisions to be in the fore-front of cancer diagnostics using latest and powerful tools by constant engagement with clinicians, academic researchers and drug developers to redefine the way cancer is treated.
CANLYTx is a revolutionary proprietary tool incorporating algorithms and data analytics to guide in precision cancer diagnosis using genetic data and drug metabolism.
CANLYTx uses data from the new-age technology for sequencing DNA and adopts validated and approved protocols. This enables quick, accurate and timely intervention for the benefit of the patients.
CANLYTx provides deep insights analyzing the entire part of the DNA that codes for all the proteins in the body and the type of drug that will be most effective from the selected ones.
CANLYTx provides an actionable accurate report to the physicians within 2-4 weeks of receiving the patient’s tissue sample.